STM2457, the selective catalytic inhibitor of METTL3, has been found to reduce the growth of acute myeloid leukemia (AML) and promote differentiation and apoptosis, thus preventing and slowing AML progression in mouse models (41). Here, METTL3 is linked to acute myeloid leukemia.